TEQCool AB is a medical technology company, based in Lund, that is developing a unique, patented solution for cooling the brain and body of Intensive Care patients who have suffered cardiac arrest.
TEQCool’s solution is based on many years of research and development at Lund University.
Extensive worldwide market potential
Every year, more than 350,000 Americans and 100,000 British suffer from cardiac arrest. Millions are affected worldwide.
Approximately, the global sales value within temperature control (mild hypothermia) exceeds 10 billion SEK per year. TEQCool’s solution is an effective aid, especially adapted to maintain normothermia (normal body temperature) and to prevent fever in cardiac arrest patients in accordance with the latest research findings, published in June 2021.
Easy and Efficient Targeted Normothermia Solution!
IR & dokument